Health Technology Assessment, 2010 Objectives: To assess the clinical effectiveness and cost-effectiveness of topotecan as second-line treatment for small cell lung cancer (SCLC). Data sources: Bibliographic databases were searched from 1990 to February 2009, including the Cochrane ...
E Loveman +6 more
doaj +2 more sources
Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening [PDF]
Cell Death and DiseaseThe topoisomerase I inhibitor topotecan is an effective chemotherapeutic agent for retinoblastoma; however, treatment resistance remains a major clinical challenge, and its mechanisms remain elusive.
Jingyi Jiang +14 more
doaj +2 more sources
Therapeutic uses of topotecan for thoracic malignancies
Oncology Reviews, 2011 Topotecan, a topoisomerase 1 inhibitor (topo1-i), is a semi-synthetic derivative of camptothecan with wellestablished cytotoxic properties. It is licensed for the treatment of relapsed, sensitive small cell lung cancer (SCLC) and for second line ...
Saoirse O. Dolly +4 more
doaj +2 more sources
Triggering of Suicidal Erythrocyte Death by Topotecan [PDF]
Cellular Physiology and Biochemistry, 2015 Background/Aims: The topoisomerase I inhibitor topotecan is used as treatment of various malignancies. The substance is effective by triggering tumor cell apoptosis. In analogy to apoptosis of nucleated cells, erythrocytes may enter eryptosis, a suicidal
Rosi Bissinger +4 more
doaj +2 more sources
In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration [PDF]
Ophthalmology SciencePurpose: To assess the stability of concentrated solutions of topotecan and the ocular and systemic safety of administering repeated very high doses of intravitreal (IVi) topotecan in rabbits. Design: Experimental study.
María J. Del Sole, PhD +8 more
doaj +2 more sources
High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma [PDF]
American Journal of Ophthalmology Case ReportsPurpose: To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans. Observations:
David H. Abramson, Jasmine H. Francis
doaj +2 more sources
Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. [PDF]
PLoS ONE, 2013 PURPOSE: Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects.
Jasmine H Francis +6 more
doaj +2 more sources
Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report [PDF]
Case Reports in OncologyIntroduction: Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse
Davien Deraedt +3 more
doaj +2 more sources
Intrathecal Chemotherapy Through Ommaya Reservoir in Leptomeningeal Metastasis From Cervical Cancer: A Rare Case Report and Literature Review. [PDF]
J Obstet Gynaecol ResABSTRACT Leptomeningeal metastasis (LM) is a rare complication of cervical cancer associated with a poor prognosis. We report a 61‐year‐old woman with stage IVB cervical squamous cell carcinoma who developed acute headache and diplopia during systemic chemotherapy.
Ahn C +7 more
europepmc +2 more sources
Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter [PDF]
, 2012 Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA ...
McCluskey, Anthony G +7 more
core +4 more sources